| Document |
Document Title |
|
WO/2023/127855A1 |
The present disclosure provides a novel synthetic intermediate of prostaglandin or an optically active substance thereof, and a production method that uses the same. More specifically, in the method according to the present disclosure fo...
|
|
WO/2023/126223A1 |
The present invention relates to novel photoinitiators having hydroxyl groups and/or (meth)acrylate groups. The invention also relates to compositions comprising these photoinitiators as well as their use for photopolymerizing ethylenica...
|
|
WO/2023/126865A1 |
The present invention relates to solid forms of Pitolisant or its salt (1). It further discloses the solid dispersions of Pitolisant or salt (1) thereof in amorphous form and at least one suitable pharmaceutically acceptable excipient. T...
|
|
WO/2023/122481A2 |
Heterobifunctional chemical linkers useful in protein degraders and other medicinal chemistry applications are provided. The heterobifunctional linkers include alkyne-piperidine and alkane-piperidine linkers; alkane- piperazine linkers; ...
|
|
WO/2023/118971A1 |
The present subject matter provides a buffer reactor system 100, and the method for enabling the production of ACRN-sulphate used in the synthesis of ATBS is disclosed. The system may comprise a tubular reactor 117, a first inlet dip pip...
|
|
WO/2023/117119A1 |
The present invention relates to the field of flavors and more specifically to new representatives of this group, in particular active ingredients having a sialagogue effect. The invention also relates to the use of these active ingredie...
|
|
WO/2023/114943A2 |
Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R3, L1, L2, G1, G2 and G3 are as defined herein. Use of the compounds as a component of lipid nan...
|
|
WO/2023/113456A1 |
The present invention relates to a compound capable of degrading a target protein by using ubiquitination, and provides a compound having a targeted protein binding moiety (TBM) structure, which binds to a target protein or polypeptide, ...
|
|
WO/2023/113457A1 |
The present invention relates to a compound capable of degrading a target protein by using ubiquitination, and provides a compound having a targeted protein binding moiety (TBM) structure, which binds to a target protein or polypeptide, ...
|
|
WO/2023/115002A1 |
The present disclosure relates to compound Formula (I) methods for making the compounds and methods for their use.
|
|
WO/2023/114366A2 |
Compounds of Formula I, Formula II, and the pharmaceutically acceptable ester, amide, solvate, salt, prodrug, or metabolite thereof, or a salt of such an ester, amide, prodrug, or metabolite, or a solvate of such an ester, amide, salt, p...
|
|
WO/2023/114188A1 |
Provided herein are compounds, such as compounds of Formula (I), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, and isotopically labeled derivatives thereof, and compositions...
|
|
WO/2023/114944A1 |
Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R2a, R2b, R3a, R3b, R7, R8, R9, L1, L2, G1, G2, G3, b, and c are as defined herein. Use of the co...
|
|
WO/2023/107648A2 |
Provided herein are compounds, such as compounds of Formula (I), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, and isotopically labeled derivatives thereof, and compositions...
|
|
WO/2023/105411A1 |
Processes for producing a N,N-dialkyl perfluoroalkyl-sulfonamide product of the formula Rf—S(O)2—NRaRb (I) in which Rf represents fully or partially fluorinated alkyl groups with carbon 1 to 12 and Ra and Rb represents linear or bran...
|
|
WO/2023/098592A1 |
The present invention provides a carbon-loaded iron-based catalyst, and a preparation method thereof and a use. The preparation method comprises dissolving ferric chloride in water, adding activated carbon, adding sodium hydroxide at 60-...
|
|
WO/2023/092242A1 |
The present application includes dendrons of Formula I, compositions comprising these dendrons and uses thereof, in particular for the delivery of agents such as nucleic acids and drugs to cells and subjects. (I) wherein each Repeating G...
|
|
WO/2023/087632A1 |
The present invention belongs to the field of medicinal chemistry, and specifically disclosed are an anti-inflammatory analgesic compound and the use thereof. The compound of the present invention is a compound having a structure shown i...
|
|
WO/2023/090974A1 |
The present invention provides a method for preparing a high-purity arylethene compound through a simple process with a high yield.
|
|
WO/2023/091490A1 |
Novel ionizable lipids and lipid nanoparticles that can be used in the delivery of therapeutic cargos are disclosed.
|
|
WO/2023/085256A1 |
The present invention provides a fluorine-containing ether compound which is represented by the following formula. R1-O-R2-CH2-R3-CH2-R4-CH2-R5-CH2-R6-CH2 -R7-CH2-R8-O-R9 (In the formula, R3, R5 and R7 represent same perfluoropolyether c...
|
|
WO/2023/085271A1 |
The present invention provides a fluorine-containing ether compound which is represented by the following formula. R1-O-R2-CH2-R3-CH2-OCH2CH(OH)CH2O-CH2-R4-CH2-R5-O-R6 (In the formula, R3 and R4 represent same or different perfluoropolye...
|
|
WO/2023/085894A1 |
The present invention relates to a novel thiourea derivative as an activator of RORα and a pharmaceutical composition comprising same. A compound according to the present invention is expected to be effective in the treatment and preven...
|
|
WO/2023/078950A1 |
The current invention relates to ionizable lipid-like compound according to Formula (I) or pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The present invention also provides a lipid nanoparticle comprising an ioniza...
|
|
WO/2023/078946A1 |
The current invention relates to ionizable lipid-like compound according to Formula (I) or pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The present invention also provides a lipid nanoparticle comprising an ioniza...
|
|
WO/2023/077235A1 |
The present invention discloses novel pentamidine analogues such as pentamidine analogs having the general formula: (1a) wherein: X is C, N, or –CH-CH-, Y is Y1 when X is N, and Y is Y1 and Y2 when X is C, or –CH-CH-, Y1, or Y1 and Y...
|
|
WO/2023/076302A1 |
A process for preparation of benzoate salt of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-h
ydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile,
designated herein as Compound (A), and methods of using Compound (A)...
|
|
WO/2023/077094A1 |
The present disclosure provides methods for the treatment of major depressive disorder (MDD) by administering cariprazine or a pharmaceutically acceptable salt thereof, as an adjunct to antidepressant therapy in the treatment of subjects...
|
|
WO/2023/074936A1 |
The present disclosure relates to a bifunctional compound using a UBR box domain-binding ligand. The UBR box domain is a domain commonly present in the UBR (Ubiquitin protein ligase E3 component n-recognin) protein of the N-end rule path...
|
|
WO/2023/066190A1 |
The disclosure relates to the compounds as GPR183 inhibitors, the methods for preparing these compounds, and the compositions and their uses as treatment or prevention of cancers, autoimmune diseases, pain, and osteoporosis using GPR183 ...
|
|
WO/2023/066971A1 |
The present invention relates to novel trimetazidine salts, leading to a reduced formation of trimetazidine nitrosamine in presence of nitrites.
|
|
WO/2022/115971A9 |
Disclosed are methods for separating, recovering, and purifying CBGA, CBDVA, THCVA, CBCVA, and CBCA from dewatered and desolventized crude complex extracts or mixtures of metabolites, cannabinoids, and cannabis phytochemicals. The method...
|
|
WO/2023/057097A1 |
The present invention is comprised in the field of medicinal chemistry, and it is related to substituted vinyl piperazine-piperidine urea compound which are well effective as antitumoral agents. In particular, they are suitable in method...
|
|
WO/2023/057358A1 |
A process for the production of bis(pyrrolidino)butane (BPB), the process comprising the reaction of pyrrolidine (PYR) in the presence of hydrogen, a heterogeneous catalyst (catalyst) and optionally 1,4-butanediole (BDO) in the liquid ph...
|
|
WO/2023/056365A2 |
The present application is directed to inhibitors of iRhom2/ADAM17 activity that are useful in the treatment of various diseases.
|
|
WO/2023/053008A1 |
The present invention relates to oximes, their synthesis, and their use for increasing GBA activity and/or levels as well as treatment of GBA-related diseases, such as Parkinson's disease.
|
|
WO/2023/046768A1 |
The invention relates a method for producing amine N-oxide compounds of the formula (I) or (II), in which the R1 are selected from hydrocarbon groups with 4 to 26 C atoms and optionally at least one O or S atom; R2, R3, and R5 are select...
|
|
WO/2023/046330A1 |
A continuous process for the separation of a mixture comprising pyrrolidine, bis(pyrrolidino)butane and water, the process comprising the following steps: A) separating a mixture stream (1) by distillation into a low-boiler stream (2) co...
|
|
WO/2023/049808A2 |
The present disclosure relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, compositions comprising same, and methods of using the compounds and compositions to treat various cancers.
|
|
WO/2023/044574A1 |
Disclosed are novel phosphorylated and sulfonated mescaline derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a precursor mescaline derivative with a...
|
|
WO/2023/043040A1 |
The present invention provides a novel compound for a light-emitting device, and an organic light-emitting device comprising same.
|
|
WO/2023/040106A1 |
Disclosed in the present invention is a preparation method for an acetamide compound by means of green visible-light catalysis. In the method, LED lamps are used as light sources to provide energy, and economically available aromatic ami...
|
|
WO/2023/036148A1 |
Provided in the present invention are a cationic lipid compound and the use thereof, which relate to the field of biomedicines. A lipid nanoparticle prepared from the cationic lipid compound as represented by formula I in the present inv...
|
|
WO/2023/036945A1 |
The invention relates to a compound of formula (I) wherein A is NH or CH2; G1 is a linear or a cyclic alkyl; Y1 is CH or N; Y2 is O, N or CH, W is O, N or CH; Z is NH or O; X1 and X2 and R, and R1 to R8 are functional groups.
|
|
WO/2023/038456A1 |
The present invention relates to a novel compound, and a use thereof for treating emotional behavioral disorders. A pharmaceutical composition containing the novel compound according to the present invention for preventing or treating em...
|
|
WO/2023/030667A1 |
A process for the preparation of a compound of formula (II) where Et = ethyl; Bn = benzyl and Ph = phenyl; comprises the step of reacting a cyclic amine with an alkylating agent to form a compound of formula II, wherein the process is so...
|
|
WO/2023/029928A1 |
An amino lipid and an application thereof: using ethenesulfonyl fluoride (ESF), a dual-function electrophile, to build an amine head group and a hydrophobic chain into an amino lipid, fully utilizing the click chemical reaction propertie...
|
|
WO/2023/033044A1 |
Provided is a fluorine-containing ether compound represented by the following formula. R1-[B]-[A]-O-CH2-R2-CH2-O-[C]-[D]-R3 (wherein, R1 denotes a C7-18 organic group including a group in which an aromatic hydrocarbon and a nitrogen atom...
|
|
WO/2023/035005A2 |
The present invention provides a dual inhibitor that inhibits histone deacetylase 6 (HDAC6) and heat shock protein 90 (HSP90) for amelioration and/or treatment of tumors through removal of immune suppression from tumor microenvironments ...
|
|
WO/2023/026884A1 |
To provide a curable composition that generates little outgas from an obtained cured product. The curable composition includes a radical polymerization initiator represented by formula 1 and a radical polymerizable compound. In formula 1...
|
